Studybox Research CLIA Waiver Studies
Point-of-Care Molecular Respiratory Panel
Accuracy in the hands of untrained intended-use operators at waived sites.
Studybox
CLIA Waiver Studies
Sample-to-answer molecular tests have been CLIA-waived since the middle of the last decade, and multiplexed respiratory panels on these platforms are now standard subjects for dual-submission programs. The clinical study compares each target to a cleared laboratory molecular method, which sets a high bar: the comparator is no longer a culture or antigen method the new device can easily outperform, and near-equivalence per analyte is the expectation.
The instrument changes the waiver question. For a lateral flow test the risk is misreading a line; for a molecular cartridge the risks are sample loading errors, cartridge handling, instrument placement and environmental conditions, and interpretation is done by software. Flex studies and the invalid-rate analysis therefore carry more of the waiver argument than operator interpretation does.
- Analyte
- Nucleic acid targets for influenza A, influenza B, RSV and SARS-CoV-2 (panel composition varies by device)
- Therapeutic area
- Infectious Disease
- Specimens
- Nasopharyngeal (NP) Swab, Anterior Nares (Nasal) Swab
- Intended-use settings
- urgent care, physician office, pharmacy, hospital POC, emergency department
- Operators
- Non-laboratory clinic staff in waived settings running a sample-to-answer instrument; laboratory staff for moderate-complexity claims.
- Comparator
- Typically one or more FDA-cleared laboratory molecular assays for each target, with discordant specimens tested by a second cleared molecular method or bidirectional sequencing where the protocol permits.
CLIA Waiver Studies specifics
What Changes for This Assay on This Pathway.
- Flex studies for an instrumented molecular device typically stress sample volume and loading, cartridge handling (delay between sample addition and insertion, temperature excursions), instrument placement (vibration, tilt, ambient temperature and humidity) and interruptions during the run.
- Invalid and error rates in untrained hands at waived sites are an endpoint in their own right, because a high error rate in waived settings undermines the simplicity argument.
- Software-reported results remove interpretation error, so the waiver argument rests on showing that the remaining user steps cannot produce a plausible wrong answer without an error flag.
Endpoints the study must support
- Positive and negative percent agreement per analyte against the molecular comparator, with 95% confidence intervals
- Invalid and error rates, including cartridge and instrument errors, by site and operator
- Performance by specimen type and age stratum, with co-infection agreement reported descriptively
Enrollment realities
Driven by the rarest analyte on the panel and by the number of waived sites running the instrument; multi-season enrollment is the norm, and instrument placement and cartridge supply at many small sites is a logistical driver of timeline. Influenza and RSV components depend on fall-to-spring circulation; SARS-CoV-2 enrollment can continue year-round, so the study typically runs continuously with analyte-specific accrual.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Waiver evidence depends on genuine intended-use operators in genuine waived settings. Our network of 100+ pre-qualified urgent care, physician office, and point-of-care sites already runs IVD protocols, so operator recruitment and site activation don't start from zero. How we run clia waiver studies →
Same assay, other pathways
Relevant FDA guidance
- Recommendations for Dual 510(k) and CLIA Waiver by Application Studies
- Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices
- Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program
- Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
Our track record here
Studies Our Team Has Run for This Test Type.
-
Dual 510(k) + CLIA waiver · Infectious disease
Dual 510(k) and CLIA Waiver Study for a Point-of-Care Molecular Flu A/B Test
A semi-automated RT-PCR test with a visual lateral-flow readout, run on a small benchtop dock, was cleared for qualitative detection and differentiation of influenza A and B RNA in nasal swabs from patients with signs and symptoms of respiratory infection. A prospective study at about 15 sites during a single season, with on-site testing by non-laboratory personnel against an FDA-cleared molecular comparator, supported a combined 510(k) and CLIA waiver review.
-
Dual 510(k) + CLIA waiver · Infectious disease
Dual 510(k) and CLIA Waiver Study for a Point-of-Care Molecular RSV Test
A semi-automated RT-PCR test with a visual lateral-flow readout was cleared for qualitative detection of respiratory syncytial virus (RSV) RNA in nasal swabs from children and adults with signs and symptoms of respiratory infection. A prospective U.S. study at about 10 sites in a single RSV season, with on-site testing by non-laboratory personnel against an FDA-cleared molecular RSV assay, supported a combined 510(k) and CLIA waiver review.
FAQ
Point-of-Care Molecular Respiratory Panel Study Questions.
01 Who operates the point-of-care molecular respiratory panel in a clia waiver studies study?
Non-laboratory clinic staff in waived settings running a sample-to-answer instrument; laboratory staff for moderate-complexity claims.
02 What is the comparator for a point-of-care molecular respiratory panel study?
Typically one or more FDA-cleared laboratory molecular assays for each target, with discordant specimens tested by a second cleared molecular method or bidirectional sequencing where the protocol permits.
03 What drives enrollment for a point-of-care molecular respiratory panel study?
Driven by the rarest analyte on the panel and by the number of waived sites running the instrument; multi-season enrollment is the norm, and instrument placement and cartridge supply at many small sites is a logistical driver of timeline. Influenza and RSV components depend on fall-to-spring circulation; SARS-CoV-2 enrollment can continue year-round, so the study typically runs continuously with analyte-specific accrual.
Let's talk IVD research
Planning a point-of-care molecular respiratory panel study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the clia waiver studies pathway.